Proceeds enable Nouscom to complete Phase 2 clinical trials with its cancer vaccine NOUS-209

M Ventures co-leads a €67.5 million oversubscribed Series C round for cancer immunotherapy company Nouscom


M Ventures is co-leading a €67.5 million oversubscribed Series C financing for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens. M Ventures co-led the round alongside Andera, Bpifrance. Concurrent with the financing, representatives from M Ventures, Andera Partners and Bpifrance have joined the Nouscom Board of Directors.

The proceeds will be used to continue advancing and expanding Nouscom’s wholly owned clinical pipeline to achieve multiple clinical value catalysts, including:

Readout from Nouscom’s ongoing randomized Phase 2 clinical trial for NOUS-209, an off-the-shelf vaccine targeting 209 shared neoantigens, in combination with pembrolizumab for the treatment of Mismatch Repair/Microsatellite Instable (dMMR/MSI) Metastatic Colorectal Cancer (mCRC).

Final readout from the ongoing Phase 1b study and advancement of NOUS-209 monotherapy in Lynch Syndrome (LS) carriers investigating the potential to intercept, prevent or delay cancer before it occurs. LS carriers have a genetic predisposition to and consequently higher risk of developing certain cancers. Promising initial results from this study were reported in a Late-breaking Abstract at the recent Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

Completion of a Phase 1b study evaluating NOUS-PEV, a personalized cancer immunotherapy, in combination with a checkpoint inhibitor in patients with advanced melanoma and entry into randomized Phase 2 trials in indications with high unmet medical needs.

This financing will allow us to further accelerate development across our wholly owned clinical portfolio reporting multiple clinical trial readouts including from our ongoing randomized Phase 2 clinical trial with NOUS-209. These Phase 2 data, if positive, have the potential to position Nouscom’s neoantigen based cancer vaccines amongst the most thrilling developments in the field.

Dr. Marina Udier, CEO of Nouscom